Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs

Abstract excerpt

Despite the fact that over 90% of HIV-1 infected people worldwide harbor non-subtype B variants of HIV-1, knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited. Due to historical delays in access to antiretroviral therapy (ART) on a worldwide basis, the vast majority of reports on drug resistance deal with subtype B infections in developed countries. However, both enzymatic and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to HIV/AIDS Research and Interventions
• Share to HIV Research and Treatment